An experimental compound inhibited clot formation without increased bleeding, a common side effect of current anticlotting therapies, in a phase I study. First-in-human study shows the anticlotting drug was well-tolerated without serious safety concerns in healthy volunteers. Next-phases will gauge effectiveness and safety in patients with acute ischemic strokes.
Source: Care Giving Science Daily
Experimental antiplatelet compound for acute stroke shows promise
April 18th, 2019 | Posted by in UncategorizedYou can follow any responses to this entry through the RSS 2.0 You can leave a response, or trackback.
Leave a Reply